key: cord-0045007-by4p0fo6
authors: Roche, Kara Long; Chi, Dennis S.
title: Practical guidelines for triage to neoadjuvant chemotherapy in advanced ovarian cancer: Big risk, big reward…or too much risk?
date: 2020-06-08
journal: Gynecol Oncol
DOI: 10.1016/j.ygyno.2020.05.003
sha: f5716c28378c13bef48f157c9057c988cddf1e0a
doc_id: 45007
cord_uid: by4p0fo6

nan

The triage of patients with advanced epithelial ovarian cancer (EOC) to neoadjuvant chemotherapy (NACT) versus primary debulking surgery (PDS) is a source of longstanding controversy within the gynecologic oncology community. Four major randomized controlled trials (RCTs) have demonstrated comparable survival outcomes between NACT and PDS, and are commonly referenced as justification for the increasing practice of triaging patients with advanced EOC to upfront chemotherapy [1] [2] [3] [4] . The generalizability of these results to the properly selected patient, however, has been called into question by fierce advocates for PDS, who cite previous prospective and retrospective studies that have consistently reported the longest survival times among patients who have undergone PDS and achieved a complete gross resection (CGR) of disease [5, 6] . Whether these improved outcomes are a result of patient selection or surgical effort and expertise (or most likely a combination of both), these data are compelling and support the continued practice of offering PDS in appropriate settings. While we await the results of the International TRUST trial, to hopefully once and for all answer the question of NACT versus PDS, we are left with the difficult task of triaging patients with advanced EOC to one of two possible upfront treatment strategies.

Two main themes arise in the pursuit of the optimal treatment paradigm for newly diagnosed EOC: predicting which patients have resectable disease and determining which patients are "fit" enough to undergo the anticipated operation. In real clinical practice, neither can be assessed in a vacuum, as the two are undeniably linked. The more extensive the necessary surgical resection, the "fitter" the patient must be to undergo and successfully recover from the surgery. The preoperative prediction of resectability has been an evolving and elusive challenge; multiple models, incorporating clinical, radiologic and intraoperative disease-related variables, have been suggested, with varying success. Determining patient "fitness" for cytoreductive surgery represents a similar challenge; various outcomes, such as length of stay, non-routine discharge, time to subsequent oncologic therapy, and of course, morbidity and mortality, can be used as benchmarks to determine the suitability of a patient population for surgical intervention.

In this issue of Gynecologic Oncology, Narasimhulu and colleagues from the Mayo Clinic report on the validation of a previously published algorithm to identify patients at highest risk for death and serious complications after primary cytoreductive surgery for stage IIIC and IV EOC [7] . The authors use the metric of postoperative morbidity/ mortality as an indicator to identify a patient population not suitable for PDS. Using the algorithm, patients are defined as "high risk" if they meet any of the following criteria: albumin b3.5 g/dL, age ≥80 years, or age 75-79 years with one other risk factor (defined as Eastern Cooperative Oncology Group [ECOG] performance status N1 or an American Society of Anesthesiologists [ASA] score of 3-4, stage IV disease, or the likely need for complex surgery) [8] . To validate this algorithm, the authors used an independent, multicenter, national dataset to amass a cohort of 1777 patients who had undergone surgery for advanced ovarian cancer. Unlike the population used to create the algorithm, patients in the validation cohort were more likely to have low surgical complexity scores (69.8% low complexity, 5% high complexity) and shorter operative times (median, 192 min).

After application of the above algorithm criteria, 28.2% of the validation cohort was deemed "high risk" and would have been triaged to NACT. High-risk patients experienced a 2-fold higher rate of severe 30-day complications or death (6.2% versus 3.5%) and a 3-fold higher rate of 30-day mortality (1.4% versus 0.5%). As expected, these findings were more pronounced in the subcohort of patients who had undergone intermediate-to high-complexity surgery, with severe complications noted in 11% of high-risk patients versus 5.7% of triageappropriate patients. These data shed light on some important trends within their study: the majority (70%) of patients had undergone lowcomplexity operations, and only modest levels of CGR (46-51%) were reported. That the algorithm developed at the Mayo clinic, an institution well known for high-complexity surgery, maintained validity in this population is a tribute to the strength of these criteria as predictors of perioperative morbidity and mortality.

As the old saying goes, "good surgeons know how to operate, better ones know when to operate, and the best when not to operate" [9] , this validated algorithm identifies the most vulnerable portion of our patient population, those in whom surgery poses a significantly increased risk of morbidity and mortality. Narasimhulu and colleagues conclude that their triage algorithm, which reliably identifies patients at increased risk of morbidity after PDS, should be used to triage patients to NACT, and potentially applied more broadly to determine surgical candidacy Gynecologic Oncology 157 (2020) 561-562 at any time during disease course. Balancing the risks and benefits of intervention is a universal tenet of surgery, and is especially challenging in advanced EOC, for which the extent of the operation is not fully appreciated until it commences. There are retrospective data, however, demonstrating that even in the face of heightened surgical risk, achieving a CGR at the time of PDS is associated with improved survival. Published data from a cohort of 141 patients who had undergone extensive upper abdominal procedures during PDS at our institution reported a 22% risk of major postoperative complications [10] . These patients, all of whom had a large tumor burden, had a median overall survival (OS) of 57 months, notably longer than in any of the abovereferenced RCTs evaluating PDS versus NACT (median OS, 22-49 months for all arms) [1] [2] [3] [4] 10] .

This leads to the question: how much risk is too much in the treatment of advanced EOC? In the current study, the high-risk group experienced a 6.2% risk of severe complications and a 1.4% risk of 30day mortality. In the face of a life-threatening malignancy, is this too much of a risk? Havrilesky et al. examined this question from the patient's perspective using a discreet choice experiment and found that patients are willing to accept a 15% increased risk of morbidity and a 4% increased risk of mortality in order to increase their expected OS from 3 to 3.5 years [11] . Reevaluating the morbidity/mortality of the high-risk patients in the validation cohort within the context of these patient preferences raises concerns regarding the universal application of these criteria to determine surgical candidacy. The validated algorithm uses 3 criteria-2 objective and 1 subject to some interpretation. We have specific reservations regarding the use of albumin b3.5 g/dL as an isolated and strict contraindication to PDS; this practice will eliminate the surgical option for a group of women who otherwise may have been able to tolerate and benefit from PDS, and this certainly warrants further investigation.

The incentives to decrease surgical complications are plentiful and compelling, and include patient pain and suffering, impaired oncologic outcomes, public reporting of complication data, financial/ reimbursement consequences, and most recently, resource preservation as evinced by the current COVID-19 pandemic. Omitting PDS, or possibly debulking surgery altogether, for high-risk patients will inevitably decrease perioperative morbidity and mortality, but it may also worsen survival and potentially increase suffering from underlying disease. We commend the authors for providing us reliable, evidence-based criteria to identify patients at heightened risk for complications. Patient selection, or knowing "when not to operate", will always be a crucial component of physician judgment; as a community, we experienced this in an unprecedented way during the recent peak of the COVID-19 pandemic, as we faced difficult practicealtering decisions in an effort to protect our patients and the health care system. However, as opposed to a rigid triage guide, we see these data as a call to action to further investigate perioperative risk and its relationship to OS, quality of life, patient preferences, and health care utilization. The development of innovative and evidence-based strategies, such as prehabilitation programs, improved surgical techniques, and optimized perioperative care, are needed to decrease complications for vulnerable patients, and in doing so, allow for more patients with EOC to reap the benefits of a successful surgical debulking.

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial

Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial)

Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602

Intraperitoneal cisplatin and paclitaxel in ovarian cancer

Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center

Less guessing, more evidence in identifying patients least fit for cytoreductive surgery in advanced ovarian cancer: A triage algorithm to individualize surgical management

Using an evidence based triage algorithm to reduce 90 day mortality after primary debulking surgery for advanced epithelial ovarian cancer

Knowing when not to operate

The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas

Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer

Outside the submitted work, Dr. Chi reports personal fees from Bovie Medical Co. (now Apyx Medical), Verthermia Inc., C Surgeries, and Biom 'Up, as well as other from Intuitive Surgical, Inc. and TransEnterix, Inc.

Drs. Long Roche and Chi contributed equally to the conception, writing/critical revision, and final approval of the manuscript.